Lovastatin decreases coenzyme Q levels in humans.
This study was conducted to find out whether Lovastatin, a statin drug with serious side effects that is used to lower cholesterol in the blood, inhibits the production of the antioxidant coenzyme Q10 in the body, thereby causing new heart disease and other adverse effects. For this purpose, 2 similar experiments were conducted. One involved patients in a hospital, the other involved a volunteer. In all study participants, Lovastatin reduced the Q10 levels and increased the risk of potentially life-threatening heart disease. In contrast, the intake of Q10 increased the levels of Q10 in the blood and led to an improvement of cardiac functions. Further details can be found in the study.
The underlying disease process of coronary artery disease (CAD) is called arteriosclerosis. This process starts with a weakening of the blood vessel walls, most frequently caused by an insufficient dietary intake of vitamins and other micronutrients. This leads to an underproduction of collagen and other reinforcement molecules in the artery walls and to the initiation of a repair process to compensate for the growing instability of the wall. The arteriosclerotic plaques that – with time – narrow the blood flow in the coronary arteries is essentially an overshooting repair process for the vitamin-deficient coronary artery wall. A heart attack occurs when the already narrowed artery is clogged and the supply of oxygen and nutrients to billions of heart muscle cells is interrupted. Angina pectoris. Angina pectoris is the typical alarm signal for an increased risk of heart attack. Angina pectoris typically manifests as a sharp pain in the middle of the chest, which frequently radiates into the left arm, but can also manifest itself in other (untypical) symptoms.
K Folkers, P Langsjoen, R Willis, P Richardson, L J Xia, C Q Ye, and H Tamagawa. Lovastatin decreases coenzyme Q levels in humans. Proc Natl Acad Sci U S A. 1990 Nov; 87(22): 8931–8934.